Literature DB >> 28705477

Association of cardio-ankle vascular index with cardiovascular risk factors and cardiovascular events in metabolic syndrome patients.

Aleksandras Laucevičius1, Ligita Ryliškytė2, Jūratė Balsytė3, Jolita Badarienė1, Roma Puronaitė4, Rokas Navickas1, Svetlana Solovjova1.   

Abstract

OBJECTIVES: We aimed to investigate the association between arterial stiffness assessed as cardio-ankle vascular index (CAVI) and cardiovascular (CV) risk factors and CV events in the middle-aged metabolic syndrome (MS) patients.
MATERIALS AND METHODS: A follow-up study was carried out in 2106 middle-aged (53.83±6.17 years old, 62% women) MS subjects without overt atherosclerotic disease. Patients were initially recruited in 2009-2011 as participants of the Lithuanian High Cardiovascular Risk (LitHiR) primary prevention program and followed up for 3.8±1.7 years for CV events. Thorough cardiometabolic risk assessment was carried out at inclusion.
RESULTS: Subjects with higher CAVI had worse lipid and glucose metabolism profile: elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C), higher fasting and oral glucose tolerance test (OGTT) glucose levels (all P<0.001), and lower fasting insulin (P=0.021). Greater age (P<0.001), heart rate (P=0.016), and mean arterial pressure (P<0.001) were also associated with higher CAVI. Over the follow-up period, 93 (4.4%) patients developed a cardiovascular event: 55 (2.6%) patients had myocardial infarction and 38 (1.8%) suffered a cerebrovascular event. Fatal CV events comprised 6.5% (n=6) of all CV events. CAVI was statistically significantly associated with occurrence of myocardial infarction (P=0.027) and total cardiovascular events (P=0.045), but not cerebrovascular events (P=0.65). However, this association was dependent on age and gender.
CONCLUSIONS: In the middle-aged MS patients, higher CAVI was associated with altered lipid and glucose metabolism, older age, greater heart rate and mean arterial pressure, and worse cardiovascular outcome.
Copyright © 2015 Lithuanian University of Health Sciences. Production and hosting by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Arterial stiffness; Cardiovascular risk; Metabolic syndrome

Year:  2015        PMID: 28705477     DOI: 10.1016/j.medici.2015.05.001

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  15 in total

Review 1.  Assessment of Arterial Stiffness Using the Cardio-Ankle Vascular Index.

Authors:  Toru Miyoshi; Hiroshi Ito
Journal:  Pulse (Basel)       Date:  2016-04-09

2.  [Predictive value of vascular health indicators on newly cardiovascular events: Preliminary validation of Beijing vascular health stratification system].

Authors:  H Liu; Y D He; J B Liu; W Huang; N Zhao; H W Zhao; X H Zhou; H Y Wang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-06-18

Review 3.  Comparison of Predictive Ability of Arterial Stiffness Parameters Including Cardio-Ankle Vascular Index, Pulse Wave Velocity and Cardio-Ankle Vascular Index0.

Authors:  Daiji Nagayama; Kentaro Fujishiro; Kenji Suzuki; Kohji Shirai
Journal:  Vasc Health Risk Manag       Date:  2022-09-12

4.  Short-Term Prognostic Impact of Arterial Stiffness in Older Adults Without Prevalent Cardiovascular Disease.

Authors:  Esther D Kim; Shoshana H Ballew; Hirofumi Tanaka; Gerardo Heiss; Josef Coresh; Kunihiro Matsushita
Journal:  Hypertension       Date:  2019-11-04       Impact factor: 10.190

5.  Cardio-ankle vascular index and cardiovascular disease: Systematic review and meta-analysis of prospective and cross-sectional studies.

Authors:  Kunihiro Matsushita; Ning Ding; Esther D Kim; Matthew Budoff; Julio A Chirinos; Bo Fernhall; Naomi M Hamburg; Kazuomi Kario; Toru Miyoshi; Hirofumi Tanaka; Raymond Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-19       Impact factor: 3.738

6.  Clinical Applications Measuring Arterial Stiffness: An Expert Consensus for the Application of Cardio-Ankle Vascular Index.

Authors:  Matthew J Budoff; Bruce Alpert; Julio A Chirinos; Bo Fernhall; Naomi Hamburg; Kazuomi Kario; Iftikhar Kullo; Kunihiro Matsushita; Toru Miyoshi; Hirofumi Tanaka; Ray Townsend; Paul Valensi
Journal:  Am J Hypertens       Date:  2022-05-10       Impact factor: 3.080

7.  Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases.

Authors:  Nahoko Tanaka; Shotaro Masuoka; Natsuko Kusunoki; Toshihiro Nanki; Shinichi Kawai
Journal:  Metabolites       Date:  2016-09-16

8.  Arterial stiffness, as monitored by cardio-ankle vascular index, is affected by obstructive sleep apnea, blood glucose control, and body weight - a case with 8 years follow up.

Authors:  Kazuhiro Shimizu; Tomoyuki Yamamoto; Kohji Shirai
Journal:  Int Med Case Rep J       Date:  2016-08-09

9.  Rationale, design, and baseline characteristics of the Cardiovascular Prognostic COUPLING Study in Japan (the COUPLING Registry).

Authors:  Kazuomi Kario; Tomoyuki Kabutoya; Takeshi Fujiwara; Keita Negishi; Masafumi Nishizawa; Mitsuyoshi Yamamoto; Kayo Yamagiwa; Akihiro Kawashima; Tetsuro Yoshida; Jun Nakazato; Yoshio Matsui; Hiromitsu Sekizuka; Hideyasu Abe; Yasuhisa Abe; Yumiko Fujita; Kei Sato; Keisuke Narita; Norihiro Tsuchiya; Yoshiaki Kubota; Toshikazu Hashizume; Satoshi Hoshide
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-24       Impact factor: 3.738

10.  Age-related difference of the association of cardiovascular risk factors with the cardio-ankle vascular index in the Cardiovascular Prognostic Coupling Study in Japan (the Coupling Registry).

Authors:  Tomoyuki Kabutoya; Satoshi Hoshide; Takeshi Fujiwara; Keita Negishi; Masafumi Nishizawa; Mitsuyoshi Yamamoto; Kayo Yamagiwa; Akihiro Kawashima; Tetsuro Yoshida; Jun Nakazato; Yoshio Matsui; Hiromitsu Sekizuka; Hideyasu Abe; Yasuhisa Abe; Yumiko Fujita; Kei Sato; Keisuke Narita; Norihiro Tsuchiya; Yoshiaki Kubota; Toshikazu Hashizume; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-06-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.